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Abstract
Water contamination with pharmaceutical products is a well-studied problem. Numerous studies have demonstrated the presence
of anticancer drugs in different water resources that failed to be eliminated by conventional wastewater treatment plants. The
purpose of this report was to conduct a systematic review of anticancer drugs in the aquatic environment. The methodology
adopted was carried out in compliance with the PRISMA guidelines. From the 75 studies that met the specific requirements for
inclusion, data extracted showed that the most common anticancer drugs studied are cyclophosphamide, tamoxifen, ifosfamide
and methotrexate with concentrations measured ranging between 0.01 and 86,200 ng/L. There was significant variation in the
methodologies employed due to lack of available guidelines to address sampling techniques, seasonal variability and analytical
strategy. The most routinely used technique for quantitative determination was found to be solid-phase extraction followed by
LC-MS analysis. The lowest reported recovery percentage was 11%, and the highest limit of detection was 1700 ng/L. This
indicated the inadequacy of some methods to analyse anticancer drugs and the failure to obtain reliable results. The significant
heterogeneity within methodologies made it difficult to compare results and draw conclusions, nevertheless, this study aids in the
extrapolation of proposed recommendations to guide future studies and reviews.
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Introduction
Pharmaceuticals are currently identified as pseudo-persistent
compounds seeing that they are constantly released into the
aquatic environment (Ebele et al. 2017). In fact, studies con-
ducted as early as the 1970s in the USA revealed the presence
of numerous pharmaceuticals in wastewater. Since then, many
improvements in analytical methodologies have facilitated the
detection of very low concentrations of pharmaceuticals in
surface water, wastewater, groundwater and drinking water
(World Health Organization 2012). According to a critical
review conducted by Stephen R. Hughes et al. in 2013, anti-
biotics, antiepileptics, cardiovascular drugs and painkillers are
the most studied compounds possibly due to frequent con-
sumption worldwide. In contrast, other potentially toxic ther-
apeutic classes such as anticancer drugs have not received
much attention (Hughes et al. 2013).
Anticancer drugs are categorised by the Anatomical
Therapeutic Chemical (ATC) classification system into two
groups according to their therapeutic, pharmacological and
chemical characteristics: antineoplastic agents (L01) and en-
docrine therapy (L02) (Besse et al. 2012). Antineoplastic
drugs are classified into five groups: L01A alkylating agents,
L01B antimetabolites, L01C plant alkaloids and other natural
products, L01D cytotoxic antibiotics and related substances
and L01X other antineoplastic agents. Meanwhile, in endo-
crine therapy, hormones (L02A), anti-hormones and related
agents (L02B) are utilised (Besse et al. 2012; Xie 2012).
The production and consumption of anticancer drugs are
on the rise corresponding to the increased incidence of cancer
worldwide (Ferrando-Climent et al. 2014). Considering their
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significant effect on human cells and hormone systems, there
is concern about the environmental risk of anticancer drugs
(Besse et al. 2012). For this reason, several studies have in-
vestigated the acute and chronic effects of anticancer drugs in
the aquatic environment: for acute toxicity, concentrations that
are likely to cause negative effects on aquatic organisms are
found to be greater than the concentrations detected in water,
except in a case of a spill (Fent et al. 2006). That means that
acute effects are very improbable. Despite the fact that there
are not many studies on chronic toxicity, some tests showed
that the concentrations detected in water were higher than the
EC50 (half maximal effective concentration) which implies
that trace concentrations of anticancer drugs in the water
may provoke adverse effects on the long-term or/and when
they are present in a mixture (Xie 2012; Booker et al. 2014;
Franquet-Griell et al. 2017; Santos et al. 2017).
Previous studies and reviews examining the occurrence of
anticancer drugs in environmental samples mainly focused on
the analytical techniques applied to detect these compounds
and their physico-chemical properties that affect their pres-
ence in the aquatic environment (Kosjek and Heath 2011;
Nussbaumer et al. 2011; Gómez-Canela et al. 2013;
Santana-Viera et al. 2016). Therefore, the aim of this report
was to conduct an exhaustive systematic review of all avail-
able studies that have investigated the presence of anticancer
drugs in the aquatic environment to date, in compliance with
the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) checklist. In addition, the corre-
sponding sampling strategies and methodologies adopted
were discussed in an effort to assess the quality and validity
of the included studies.
Throughout this review, surface water, groundwater, waste-
water and drinking water will be referred to using the term
“aquatic environment”.
Selection process
A preliminary literature search was conducted on different
databases and PROSPERO to check if the subject is qualified
for a review by the number and type of publications found and
to ensure that a similar review was not already published.
Following the scoping searches, a review protocol was made
and registered in PROSPERO (number of registration:
CRD42018100457).
In order to develop the inclusion criteria, a PICO table,
shown in Table 1, was generated including the Population,
Intervention, Comparator, Outcome and the Study Design.
All original studies written in English, published or not
(Grey literature), that assess at least one anticancer drug were
included in this review with no restriction on the year of the
study. Also, all types of findings were included (positive and
negative) in a way to reduce publication bias and to have a
representative search of all of the studies conducted.
Editorials, newspaper articles, reviews or other forms of pop-
ular media were excluded. In addition, studies that treat other
matrices than water or analyse the elimination or the stability
of anticancer drugs were rejected.
In the interest of identifying as many significant papers as
possible, published or not, a review was conducted through a
search on PubMed and OpenGrey on June 25, 2018.
Simultaneously, the same research was applied to the database
ScienceDirect to verify that no other significant publications
were available. The searched terms were combined using
Boolean operators and wildcards: (Pharmaceutical* OR
Anticancer$ OR Antineoplastic$ OR Cytotoxic$ OR Drug$
OR Organic OR Cytostatic$ OR Residue$ OR PhA OR
PhAC) AND (Detection OR Extraction OR Occurrence OR
Analysis OR Determination OR Incidence OR Assessment)
AND (*Water* OR Wastewater OR Aquatic OR River OR
Sewage) AND (SPE OR Solid-phase extraction OR LC OR
Chromatography OR Liquid Chromatography).
The initial search on PubMed covered 23,766 publications
from 1964 until the present, while OpenGrey reported only
128 studies from 1993 until 2013. It was refined by:
Languages = English (PubMed and OpenGrey) and Sort by
= Best Match (PubMed). Therefore, the study was narrowed
to 5575 publications from PubMed and 46 from OpenGrey.
Two stages were required to apply the inclusion
criteria as reported by PRISMA. Firstly, articles were
selected according to the title and abstract. All studies
that do not appear to meet all criteria were excluded,
whereas, if it is unclear that all the inclusion criteria
were met, the publication was included for further study.
After the screening stage, the full texts of the remaining
publications were obtained to select the articles that sub-
stantially met the eligibility criteria. All the rejected ref-
erences were reported with the reason of exclusion in the
PRISMA diagram. Furthermore, bibliographies of ex-
cluded and included studies were examined to determine
more pertinent publications that might be missed during
the research. The screening and selection steps were ac-
complished by two reviewers independently. The rele-
vance of each study was assessed according to the inclu-
sion criteria stated in Table 1, and any disagreement was
resolved by consensus.
The next task was to examine the quality of each of these
studies, which meant the evaluation of the validity, reliability
and generalisability of the results. To accomplish this, the
number of anticancer drugs tested was considered as the sam-
pling strategy, if the number of samples was representative, if
the methods of extraction and analysis were optimised and
validated and, finally, how the results were reported.
In this review, two types of data were extracted: the de-
scriptive data, which includes the study, the year, the country,
the compound tested, the strategy of sampling, the number of
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samples and the extraction, separation and detection tech-
niques, and the analytical data, which covers the outcomes
(number of detections and no detections and the concentration
of each compound found in the water cycle). All data were
extracted by one reviewer and checked for accuracy by a
second reviewer.
Following the refined search on PubMed and OpenGrey,
5621 citations were identified in total to be screened and
selected for inclusion. Titles and abstracts were assessed,
determining 285 publications (Stage 1 screening), by which
their full texts were obtained. Afterwards, the inclusion
criteria were applied to the full text (Stage 2 selection),
resulting in 58 citations being retained, while 197 studies
were excluded for not analysing at least 1 anticancer drug;
10 reviews were eliminated; 12 others did not assess water
samples; 4 articles which studied the elimination of antican-
cer drugs and 4 which examined their stability were rejected.
In addition, 17 publications were included from bibliography
searches. The study selection process is shown in the
PRISMA diagram (Fig. 1).
Data extraction
About 75 studies met the inclusion criteria and were subse-
quently reviewed in order to extract the information needed to
complete the review. The data were arranged in Table S1
(Supplementary Information 1) and included the publication
reference, the year the study was conducted, the country
where the samples were taken, the anticancer drug tested,
the type and number of water samples examined, the methods
of the analysis and the resulting concentrations reported in ng/
L to facilitate the comparison between different studies.
The studies were analysed considering the following pa-
rameters: geographical representation, choice of anticancer
studied, sampling strategy and analytical techniques.
Geographical representation
From the reviewedmanuscripts, the earliest study was in 1996
(Steger-Hartmann et al. 1996). The majority of the studies
Fig. 1 Identification of included
studies in the systematic review
Table 1 Eligibility criteria (PICO
table) Eligibility criteria
Population All types of anticancer drugs studied in the aquatic environment
Intervention All types of sampling strategies, extraction and analytical techniques
Comparator The stated interventions will be compared with each other
Outcome Any positive or negative results will be included
Study design Original studies; studies that analyse at least one anticancer drug
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were conducted in Spain (24 studies) and the UK (13 studies).
Therefore, fewer investigations have been conducted in other
countries. Thus, the global scope of the problem cannot be
assessed. Moreover, studies conducted in each country fo-
cused on specific areas, limiting representation.
Frequently studied compounds
Among the 75 included publications, the 4 most studied anti-
cancer agents were cyclophosphamide (39), tamoxifen (30),
ifosfamide (29) and methotrexate (17), possibly because they
are the most commonly used anticancer drugs in the corre-
sponding countries (Tauxe-Wuersch et al. 2006; Yin et al.
2010b). Concentrations of the alkylating agents, cyclophos-
phamide and ifosfamide, ranged from 0.05 to 22,100 ng/L and
from 0.14 to 86,200 ng/L in 24 and 16 studies, respectively.
The antimetabolite, methotrexate, was detected at concentra-
tions between 1.6 and 4756 ng/L in 13 studies out of 17.
Finally, the hormonal agent, tamoxifen, was identified in 19
articles with concentrations varying between 0.01 and 740 ng/
L (Fig. 2).
Additionally, active metabolites of other anticancer drugs
were studied and detected in water samples. These include
endoxifen (OH-D-TAM), (Z)-4-hydroxytamoxifen (OH-
TAM), hydroxymethotrexate (OH-MET), hydroxypaclitaxel
(OH-PAC), 1-β-d-arabinofuranoside (AraU) and 2’,2’-
difluorodeoxyuridine (dFdU) (Santana-Viera et al. 2016)
(Table S1).
The included studies revealed that diverse methodological
approaches were adopted to measure anticancer drugs in the
aquatic environment. This could explain the significant varia-
tion in anticancer concentrations detected in these studies.
Moreover, sample sources also seemed to affect the results
obtained. Consequently, studies demonstrated that the detec-
tion of anticancer compounds can be affected by several ex-
ternal factors, hence limiting the ability to compare different
studies and infer conclusions.
The diversity in employed methodologies was due to sev-
eral variability factors that will be discussed below.
Variability factors
Sample source
Sample sources ranged mainly from wastewater from hospi-
tals, influent and effluent of wastewater treatment plants
(WWTP) and surface water (Fig. 3). Results showed that the
concentrations of anticancer drugs can fluctuate if the sam-
pling was near the hospital or in rural or urban areas
(Iglesias et al. 2014). Also, results changed according to the
Fig. 2 Summary of the findings
for the four most frequently
studied anticancer drugs
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size of the hospital, the number of patients treated, the pres-
ence of specific departments (if it only treats cancer or not),
the drugs used for cancer therapy, the consumption rate and
the day of the sampling (some studies demonstrated a differ-
ence between weekday samples and weekend samples due to
the reduced therapy on weekends) (Steger-Hartmann et al.
1996; Verlicchi et al. 2012; Rabii et al. 2014; Česen et al.
2015, 2016). In Weissbrodt et al.’s study, 5-fluorouracil was
assumed to be highly detected in the hospital wastewater since
it was the most consumed anticancer drug in Cantonal hospital
and especially on Wednesday when it was administered the
most (Weissbrodt et al. 2009).
In general, concentrations are higher in hospitals’wastewa-
ter or wastewater influents than wastewater treatment plant
effluents and surface water (mainly from rivers) taking into
consideration the dilution factor, the elimination or inactiva-
tion by WWTPs or the adsorption of some compounds onto
sludge. Numerous studies demonstrated this matter such as the
survey conducted by Roberts and Thomas on tamoxifen.
Concentrations of this compound ranged between 376 and
740 ng/L in pretreated wastewater, decreased to 146–369 ng/
L in treated wastewater and to 27–212 ng/L in surface water
(Roberts and Thomas 2006). This can be explained by the
dilution factor, the characteristics of the sampling location
(e.g. width, depth, flow rate of the water), the type of waste-
water treatment performed in each plant and its elimination
efficiency (López-Serna et al. 2012; Osorio et al. 2012; Idder
et al. 2013). For instance, a typical example of elimination
studies on some anticancer drugs revealed that cyclophospha-
mide, ifosfamide, vinblastine, vincristine, etoposide, doxoru-
bicin, epirubicin, daunorubicin and cisplatin are not biode-
gradable, whereas 5-fluorouracil showed negative and
positive results. It also seemed that degradation was not as
prevalent in the presence of other anticancer compounds,
when within a mixture (Kosjek and Heath 2011). Moreover,
cyclophosphamide, ifosfamide and 5-fluorouracil appeared to
not adsorb onto sludge or sediments and did not undergo
direct photolysis demonstrated by their high persistence in
the environment (Kiffmeyer et al. 1998; Buerge et al. 2006;
Kosjek and Heath 2011).
Sampling strategy
The different sampling methods for the four most studied
compounds are reported in Table S2 (Supplementary
Information 1). It is apparent that no standardised sampling
strategy has been adopted in all of the included studies seeing
that the number of samples ranged from 1 to 105. In conse-
quence, the focus of most of the papers was on the develop-
ment of the analytical methods and their validation using en-
vironmental samples rather than obtaining a representative
number of samples that can accurately illustrate the variable
levels of anticancer drugs persisting in the aquatic environ-
ment. Additionally, the majority of the samples were collected
as 24 h composite samples or as grab samples. In Busetti
et al.’s study, comparison between these two types of sampling
was carried out. Results demonstrated that composite samples
were more representative and showed less variations in the
concentrations, whereas concentrations obtained from grab
samples appeared to be more irregular and time-dependent
(Busetti et al. 2009). In some cases, obtaining composite sam-
ples could be very challenging since hospitals or treatment
plants need to authorise it (Yin et al. 2010a). In a critical
review completed by Ort et al. (2010), the authors recom-
mended to provide more details about the sampling strategy
in order to prevent the uncertainty of the results obtained and
the misleading interpretations taking into consideration sever-
al factors such as the goal of the study, the sampling mode and
frequency and location, etc. For example, for analytical
methods development or for qualitative studies, grab sampling
can be sufficient, whereas for screening studies, composite
samples are more recommended.
Season variability
In addition, variation can be observed depending on the period
of the sampling. Some researchers collected their samples
from rivers, WWTP and hospitals effluent in hot weather sea-
sons to prevent dilution by rainfalls and high water flows
(Ashton et al. 2004; Verlicchi et al. 2012). In contrast, many
studies demonstrated that greater concentrations are detected
in winter (in river samples and wastewater influent and efflu-
ent) due to the low temperatures and reduced radiation from
the sun, which limits the biodegradation of pharmaceuticals
(Osorio et al. 2012; Kot-Wasik et al. 2016). However, one
Fig. 3 Sample sources ((A) raw wastewater from (1) households, (2)
hospitals or (3) industries; (B) influent of wastewater treatment plants or
untreated wastewater; (C) effluent of wastewater treatment plants or treat-
ed wastewater; (D) surface water, sea, etc.)
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study showed that the concentration of cyclophosphamide
was not affected by the change of seasons (Rabii et al.
2014). Nevertheless, the results of this study could not be
confirmed since the WWTP influent and effluent samples
were not collected under the same conditions (different con-
sumption rate of this drug on these sampling days and/or col-
lection of samples at different time which can affect the con-
centration of the anticancer drug in the wastewater (e.g. morn-
ing urine)).
Target compound
The presence or the absence of an anticancer drug in the
aquatic environment is affected by the form of its elimination
from the body: parent compound or metabolised form (Yin
et al. 2010a; Gómez-Canela et al. 2014) and the corresponding
stability in the water when excreted (Garcia-Ac et al. 2009a;
Negreira et al. 2014a). Studies conducted by Gomez-Canela
et al. and Yin et al. in 2012 and 2009, respectively, observed
high excretion rates for some anticancer agents, e.g.
gemcitabine, 92–98% (urine); megestrol, 66% (urine) and
20% (faeces); methotrexate, 60–95% (urine); etoposide, 44–
60% (urine) and > 16% (faeces); cyclophosphamide, 5–25%
(urine) and 31–66% (faeces); ifosfamide, 14–50% (urine); and
tamoxifen, 9–13% (urine) and 26–65% (faeces), among others
(Yin et al. 2010a; Gómez-Canela et al. 2013). This can also
mislead the interpretation of the results obtained since the
absence of one parent compound can be explained by the
presence of its metabolite.
Sample storage
Determination of suitable conditions to preserve water sam-
ples was essential considering that concentrations of antican-
cer drugs in environmental samples can easily change and be
underestimated. Also, after the sampling procedure, water
cannot always be analysed in the same day. In consequence,
stability tests were carried out for numerous anticancer drugs
in which variations of time, temperature and pH were made to
determine the ideal storage conditions of wastewater samples.
Results showed that some anticancer drugs are hydrophilic
and may persist more in the aquatic environment e.g.
ifosfamide, cyclophosphamide and 5-fluorouracil, among
others. Additionally, preservation of water samples at -20 °C
showed better recoveries than 4 °C and 25°C for most of the
compounds where degradation started to increase gradually
with the temperature. Besides, acidification of samples in-
creased the stability of some compounds like 5-fluorouracil,
vinorelbine, erlotinib and capacetabine, but may degrade
others such as ifosfamide. For this reason, it is recommended
to freeze the samples directly after collection at -20 °C and
analyse them as soon as possible (Ferrando-Climent et al.
2013; Negreira et al. 2014a, b).
Extraction and determination techniques
Extraction
Pretreatment of environmental samples is an essential step seeing
the complexity of the matrix (indicating the constituents of the
sample other than the analyte of interest) and the low concentra-
tions of the compounds resided in the aquatic environment. The
purpose of this step is to concentrate the analytes in question
while trying to eliminate probable interferences (Chapuis et al.
2005). The majority of the included studies used solid-phase
extraction (SPE) for the sample preparation consisting of the
extraction and the preconcentration of anticancer drugs
(Table S3). Solid-phase extraction can be operated in offline
and online modes. In studies that adopted offline SPE, numerous
cartridges were used demonstrating different extraction efficien-
cies for anticancer compounds. This indicates that the choice of
the right type of cartridges depends on the nature of the sorbent
and its ability to retain the anticancer drug of interest. Oasis HLB
cartridges has offered a good hydrophilic and lipophilic balance
allowing the retention of a large range of compounds. For this
reason, Oasis HLB cartridges were utilised in the majority of the
studies, since better recoveries were obtained for several antican-
cer drugs with different physico-chemical characteristics
(Ferrando-Climent et al. 2013). For anthracycline compounds,
C8 columns appeared to be the most adequate especially for
epirubicin, doxorubicin and daunorubicin (Mahnik et al. 2007).
However, in multi-residue methods, Strata-X cartridges have not
provided good recovery percentages for tamoxifen (Nebot et al.
2007). The cartridges employed in online SPE were Strata-X,
HySphere Resin GP, PLRP-s and Hypersil GOLD PFP. Strata-
X cartridges were mostly utilised, providing good recoveries for
cyclophosphamide, methotrexate and ifosfamide (Garcia-Ac
et al. 2009a, 2009b, 2011; Idder et al. 2013). Analysis performed
automatically showed higher recovery rates and improved sensi-
tivity for the detection of anticancer agents. In fact, online SPE
proved to be more convenient since it is a faster method, de-
mands a smaller volume of sample, decreases sample loss
throughout themanipulation and reduces impurity contamination
(Kosjek and Heath 2011; Santana-Viera et al. 2016). Along with
selecting the right cartridges, several parameters require optimi-
sation for a higher recovery, including the elution solution. In
general, polar solvents were used to elute the compounds of
interest such as acetone, methanol and acetonitrile. Besides, gra-
dient elution was also applied using online SPE for better extrac-
tion efficiencies (Garcia-Ac et al. 2009a, b, 2011).
Analytical techniques
HPLC-MS2 was mostly used for the separation and detection of
anticancer drugs (Table S3). Studies revealed that this technique
was more suitable and offered higher sensitivity than GC-MS,
avoiding a derivatization step, sincemost of these compounds are
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susceptible to degradation at high temperatures and have low
volatility and high molecular weight (Kosjek and Heath 2011).
Also, electrospray ionisation (ESI) seemed to be themost utilised
ionisation technique applied among others. For instance, a com-
parison of different methods of ionisation was made by Garcia-
Ac et al. to finally conclude that ESI has higher sensitivity and
selectivity (Garcia-Ac et al. 2011). However, in some studies
using GC-MS, a lower limit of detection was achieved for some
compounds such as 5-Fluorouracil (5-FU) (Kosjek et al. 2013).
Additionally, other analytical techniques were employed with
good results for specific compounds. For example, capillary elec-
trophoresis with diode array detection was used for 5-FU deter-
mination enhancing the separation rate and selectivity with a
lesser sample volume. In addition, it is faster than HPLC and
inexpensive (Mahnik et al. 2004, 2007). Inductively coupled
plasma mass spectrometry was used for the detection of
platinum-based anticancer drugs such as cisplatin (Vidmar et al.
2015; Isidori et al. 2016).
Validation parameters
The majority of the studies included in this review developed
and validated their own methods. Validation was achieved
using reference standards of each compound prepared in suit-
able solvents, mainly methanol or a mixture of water and
methanol (Nebot et al. 2007; Busetti et al. 2009; Garcia-Ac
et al. 2011). The conducted calibration plot over the analytical
working range achieved linearity with a correlation coefficient
(R2) between 0.97 and 0.99. The precision, expressed as a
percentage of the relative standard deviation, should be small-
er than 20% for water analysis (Camacho-Muñoz et al. 2016),
whereas it went from 0.1 reaching 80%, which means that
some of the given results are not reliable.
Overall, in the 75 publications examined, the accuracy of the
method expressed as recovery percentage, ranged from 11 to
167% and limits of detection varied from 0.003 to 1700 ng/L.
Low recovery percentages and high LODs in some studies indi-
cated that the adopted methods were inadequate to analyse some
compounds in environmental samples. Also, a low recovery rate
meant that themethod is validated but will require a lot of starting
material – higher sample volume as well as higher solvent vol-
ume – and an instrument with higher sensitivity.
Finally, it is important to note that environmental water
samples are complex matrixes which means that co-elution
of different organic compounds can occur and modify the
ionisation performance by enhancing or suppressing the con-
centrations of the targeted substances. For this reason, to val-
idate a reliable HPLC-ESI-MS-MS method, matrix effects
should be studied (Taylor 2005). Numerous studies evaluated
the matrix effect on the detection of anticancer drugs. For
example, in one study, signal enhancement was apparent for
cyclophosphamide and methotrexate, while signal suppres-
sion was detected for gemcitabine, epirubicin, ifosfamide
and irinotecan (Rabii et al. 2014). These matrix effects should
not be neglected, and effort should be made to reduce them
such as using isotopically labelled internal standards, amelio-
rating the sample preparation or reducing the flow rate
(Kloepfer et al. 2005). Whenever possible, the deuterated
form of the compounds analysed has been employed (e.g.
cyclophosphamide-d6, paclitaxel-d5, etc.) or isotopically la-
belled compounds such as 13C-phenacetin and 13C3-caffeine.
Also, in one study, matrix-matched calibration was performed
to correct the matrix effect (Kot-Wasik et al. 2016). For sam-
ple preparation, centrifuging and filtration always preceded
SPE in order to remove suspended solids and bacteria.
Filters used consisted of glass microfiber, cellulose nitrate,
cellulose acetate or nylon filters with pore size reaching 0.45
μm. Further clean-up of the samples was achieved when using
two cartridges in tandem (Liu et al. 2010; Yin et al. 2010a;
Camacho-Muñoz and Kasprzyk-Hordern 2015).
Research gaps and recommendations
This systematic review was developed in accordance with the
PRISMA 2009 checklist (Supplementary Information 2). The
main purpose of this research was to review publications in
which anticancer drugs were analysed in the aquatic environ-
ment. A small number of countries were represented in exam-
ining anticancer compounds and studies focused on one spe-
cific area in each country.
With the growing interest of detecting anticancer drugs in
the aquatic environment, several extraction and analytical
methods were established with most combinations applying
SPE followed by LC-MS-MS. Overall, the majority of anti-
cancer drugs analysed and detected in the 75 included studies
are cyclophosphamide, tamoxifen, ifosfamide and methotrex-
ate which correlates with them being among the most fre-
quently used drugs in cancer therapy.
In summary, the main recommendations extrapolated from
this systematic review are as follows:
& Research needs to be broadened, geographically speaking,
in order to understand the scope of the problem.
& Guidelines for sampling strategies are required to submit
reliable and representative results.
& The choice of anticancer drugs to be analysed in the water
should depend on the consumption rate of this specific
drug and whether it is administered in the addressed hos-
pital or in the surveyed area.
& Researchers should roughly predict the different com-
pounds (parent compound or metabolite) expected to be
present in their samples based on the percentage of excre-
tion of the anticancer drug, its elimination form and its
stability in the water.
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& More work needs to be done in terms of developing spe-
cific and efficient analytical methods, in order to reach
higher sensitivity and selectivity of some anticancer drugs.
& The different variability factors should be taken into con-
sideration while discussing the results obtained in order to
be certain whether the compound exist in the aquatic en-
vironment or not.
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